The International conference on leukemia and Hematologic Oncology convoked by Conference Series LLC during October17-18, 2016 was successfully held at Rome, Italy with a theme “Solution Eradicate to Hematologic Oncology” was a great success where eminent keynote speakers from various reputed institutions with their resplendent presence addressed the gathering.

Thanks to all our momentous speakers, conference attendees who contributed towards the successful run of the conference.

Hematologic Oncology 2016 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the fields of Leukemia, Hematologic Oncology, Haematology, Paediatric and Hematologic Oncology.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

·         Leukemia

·         Hemotology

·         Hematologic-oncology

·         Oncology

·         Paediatric Oncology

·         Clinical Oncology

·         Oncologists

·         Blood Disorders and Blood oncology

·         Leukemia Causes and symptoms

·         Leukemia Pathophysiology

·         Leukemia risk factors

·         Leukemia:Staging

·         Leukemia: Diagnosis

·         Leukemia immunology

·         Oncology Case Report

·         Hemato Immunology &Stem Cell Research

·         Cancer and pharmacology

·         Cancer: Treatment and Therapy

·         Cancer :Diagnostics and Staging

·         Cancer and Alternative Medicine

·         Haematological malignancies

·         Haematological malignancies: Prognosis

·         Childhood Hematological Cancers

·         Biomarkers

·         Leukemia :Treatments and care

·         Bone Marrow Transplantation and surgery

·         Advance in Bone Marrow Transplantation

·         Cancer Clinical Trials

Hematologic Oncology 2016 Organizing Committee would like to thank the Moderator of the conference, Jan Jacques Michiels, Goodheart Institute & Foundation in Nature Medicine & Health,Netherlands, who has contributed a lot for the smooth functioning of this event.

Our special thanks to David J Bearss, Tolero Pharmaceuticals, USA for his special participation as Key Note Speaker titled “Sequential treatment of AML patients with Alvocidib followed by Cytarabine and Mitoxantrone is highly effective through a mechanism dependent on MCL1 expression and function” which marked the special attraction at the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following topics were highlighted as Symposium and Special sessions:

Chronic lymphocytic leukemia: Risk factors and complications & The Diagnostic and prognostic value of CD38 and CD49d Expressions in chronic lymphocytic leukemia- Olfat M Hendy, Menoufia University, Egypt.

Diagnosis and treatment of DVT and prevention of DVT recurrence and the PTS: Bridging the gap between DVT and PTS in the primary care setting or outpatient ward - Jan Jacques Michiels, Good heart Institute, Netherlands.

Inhibition of AXL kinase reverses the mesenchymal phenotype in leukemia cells through the disruption of retinoic acid signalling - Steven L. Warner, Tolero Pharmaceuticals, Inc., USA

Conference Series LLC is privileged to felicitate Hematologic Oncology 2016 Organizing Committee, Chairs & Co-Chairs who supported for the success of this event. Conference Series LLC would like to thank every individual participant for the enormous exquisite response. This inspires us to continue organizing events and conferences for further research in the field of Hematologic Oncology.

With the valuable feedback received from the participants of Hematologic Oncology 2016,Conference Series LLC is glad to announce the commencement of “9^th International conference on leukemia and Hematologic Oncology  during October 05-06, 2017 London,UK. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of managing Leukemia and Hematologic Oncology and its concomitant risk factors.

Let us meet again @ Hematologic Oncology 2017